KOREA WHO
-
-
CEO and President of HLB Life Science
Baek Yoon-ki
Daewoo Finance Veteran Faces Hepatitis Drug Commercialization Challenge
-
Last Updated on Nov 5, 2026
-
CEO and President of HLB Life Science
Copy Url : https://www.koreawho.com/profile/BaekYoonki- Life Summary
Baek Yoon-ki is president and CEO of HLB Life Science.
He was born on April 20, 1963.
He graduated from Jeonbuk National University with a degree in business administration and studied at Sogang University's Graduate School of Business.
He worked at Daewoo Motor before serving as vice president of the Finance Department at Daewoo Capital.
In 2014, he was appointed CEO of YG Partners.
He served as executive vice president at Next Science and HLB Life Science.
After serving as CEO of HLB, he has served as CEO of HLB Life Science since 2026.
He is focusing on obtaining U.S. Food and Drug Administration (FDA) approval for the liver cancer drug rivoceranib and generating revenue through its commercialization.
#BaekYoonKi #HLBLifeScience #ChiefExecutiveOfficer #CorporateLeadership #Rivoceranib #LiverCancerTreatment #FDAApproval #DrugCommercialization #DaewooCapital #Biopharmaceuticals
He was born on April 20, 1963.
He graduated from Jeonbuk National University with a degree in business administration and studied at Sogang University's Graduate School of Business.
He worked at Daewoo Motor before serving as vice president of the Finance Department at Daewoo Capital.
In 2014, he was appointed CEO of YG Partners.
He served as executive vice president at Next Science and HLB Life Science.
After serving as CEO of HLB, he has served as CEO of HLB Life Science since 2026.
He is focusing on obtaining U.S. Food and Drug Administration (FDA) approval for the liver cancer drug rivoceranib and generating revenue through its commercialization.
#BaekYoonKi #HLBLifeScience #ChiefExecutiveOfficer #CorporateLeadership #Rivoceranib #LiverCancerTreatment #FDAApproval #DrugCommercialization #DaewooCapital #Biopharmaceuticals
- Life Summary
- Career Highlights & Challenges
- · First-Half Revenue Rises, Operating Loss Widens
- · Fourth FDA Approval Attempt for Liver Cancer Drug
- · Acquires KRW 36 Billion Stake in HLB Innovation
- · Subsidiary Wins Series of Government Research Projects
- · Executives Buy Company Shares on Open Market
- · Syringe Products Obtain International Medical Device Certification
- · Decides to Issue KRW 10 Billion in Convertible Bonds
- · Signs Exclusive Korean Distribution Deal for Human Tissue Grafts
- · HLB Group Consolidates Operations at Hakdong Headquarters
- · Restructures Organization to Improve Management Efficiency
- · Serves as CEO of HLB
- · Shifts Business Focus to Biotechnology
- · HLB Life Science Ownership Structure
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Additional Information
- Notable Quotations
- Infographic & Photos